Sufenta preservative free, Zalviso(sufentanil)
Dzuveo, Sufenta, Sufentanil (sufentanil) is a small molecule pharmaceutical. Sufentanil was first approved as Sufenta preservative free on 1984-05-04. It is used to treat pain in the USA. It has been approved in Europe to treat pain and postoperative pain. The pharmaceutical is active against mu-type opioid receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Sufenta, Sufentanil (discontinued: Dsuvia, Sufentanil)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Sufentanil citrate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SUFENTA PRESERVATIVE FREE | Rising Pharmaceuticals | N-019050 RX | 1984-05-04 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| dsuvia | New Drug Application | 2023-12-18 |
| sufenta | New Drug Application | 2010-11-15 |
| sufentanil citrate | ANDA | 2025-01-07 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| pain | EFO_0003843 | D010146 | R52 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Sufentanil Citrate, Dsuvia, Vertical Pharms | |||
| 11672738 | 2038-02-02 | DP | |
| 8945592 | 2031-07-29 | DP | |
| 8202535 | 2030-10-22 | U-1351 | |
| 8865743 | 2030-10-22 | U-1351 | |
| 8574189 | 2030-03-16 | DP | |
| 10896751 | 2030-03-16 | DP | |
| 11676691 | 2030-03-16 | DP | |
| 8226978 | 2027-01-05 | DP | U-1351 |
| 8231900 | 2027-01-05 | DP | |
| 8252328 | 2027-01-05 | DP | |
| 8252329 | 2027-01-05 | DP | |
| 8535714 | 2027-01-05 | DP | U-1351 |
| 8778393 | 2027-01-05 | U-1351 | |
| 8778394 | 2027-01-05 | U-1351 | |
| 8865211 | 2027-01-05 | U-1351 | |
| 9320710 | 2027-01-05 | U-1351 | |
| 9744129 | 2027-01-05 | DP | |
| 10245228 | 2027-01-05 | DP | U-1351 |
| 10342762 | 2027-01-05 | DP | |
| 10507180 | 2027-01-05 | DP | U-1351 |
HCPCS
No data
Clinical
Clinical Trials
539 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Postoperative pain | D010149 | — | G89.18 | 1 | 5 | 11 | 22 | 32 | 70 |
| Anesthesia | D000758 | — | — | 1 | 1 | 4 | 8 | 22 | 36 |
| Pain | D010146 | EFO_0003843 | R52 | 1 | 7 | 4 | 14 | 10 | 32 |
| Analgesia | D000698 | — | — | — | 3 | 2 | 7 | 16 | 28 |
| Delirium | D003693 | — | R41.0 | 2 | — | 1 | 7 | 10 | 20 |
| Agnosia | D000377 | EFO_0007136 | F88 | — | 1 | 1 | 8 | 10 | 19 |
| Labor pain | D048949 | — | — | — | 2 | 2 | 4 | 11 | 19 |
| Emergence delirium | D000071257 | — | — | 2 | — | — | 6 | 9 | 17 |
| Acute pain | D059787 | — | R52 | — | 1 | 4 | 8 | 3 | 16 |
| General anesthesia | D000768 | — | — | — | — | 1 | 2 | 8 | 11 |
Show 123 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Nerve block | D009407 | — | — | — | — | 1 | — | 6 | 7 |
| Local anesthesia | D000772 | — | — | — | — | 1 | — | 3 | 4 |
| Cough | D003371 | — | R05 | — | — | 1 | — | 2 | 3 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | — | 1 | — | 2 | 3 |
| Ischemia | D007511 | EFO_0000556 | — | 1 | 1 | 1 | — | 1 | 3 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | — | — | 1 | — | 1 | 2 |
| Esophageal neoplasms | D004938 | — | C15 | — | 1 | 1 | — | 1 | 2 |
| Premedication | D011292 | — | — | — | 2 | 2 | — | — | 2 |
| Shoulder injuries | D000070599 | — | — | — | — | 1 | — | 1 | 2 |
| Supratentorial neoplasms | D015173 | — | C71.0 | — | — | 1 | — | 1 | 2 |
Show 16 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | — | 1 | — | — | 5 | 6 |
| Hemorrhage | D006470 | MP_0001914 | R58 | 1 | 1 | — | — | 2 | 3 |
| Anxiety | D001007 | EFO_0005230 | F41.1 | — | 1 | — | — | 1 | 2 |
| Prenatal diagnosis | D011296 | — | — | — | 1 | — | — | — | 1 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 1 | — | — | — | 1 |
| Fibrosis | D005355 | — | — | — | 1 | — | — | — | 1 |
| Craniocerebral trauma | D006259 | — | S00 | — | 1 | — | — | — | 1 |
| Hip prosthesis | D006622 | — | — | — | 1 | — | — | — | 1 |
| Pulpitis | D011671 | EFO_1001139 | K04.0 | — | 1 | — | — | — | 1 |
| Breakthrough pain | D059390 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lung neoplasms | D008175 | — | C34.90 | 1 | — | — | — | 3 | 4 |
| Respiratory insufficiency | D012131 | — | J96.9 | 1 | — | — | — | 2 | 3 |
| Pharmacokinetics | D010599 | — | — | 2 | — | — | — | — | 2 |
| Biological availability | D001682 | — | — | 1 | — | — | — | — | 1 |
| Femur head necrosis | D005271 | — | — | 1 | — | — | — | — | 1 |
| Necrosis | D009336 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Nociceptive pain | D059226 | — | — | — | — | — | — | 5 | 5 |
| Colorectal neoplasms | D015179 | — | — | — | — | — | — | 4 | 4 |
| Gastrointestinal endoscopy | D016099 | — | — | — | — | — | — | 4 | 4 |
| Aortic dissection | D000784 | — | I71.0 | — | — | — | — | 3 | 3 |
| Hyperalgesia | D006930 | — | — | — | — | — | — | 3 | 3 |
| Individuality | D007206 | — | — | — | — | — | — | 3 | 3 |
| Airway management | D058109 | — | — | — | — | — | — | 3 | 3 |
| Anesthesia recovery period | D000762 | — | — | — | — | — | — | 3 | 3 |
| Obstetrical analgesia | D016362 | — | — | — | — | — | — | 2 | 2 |
| Pruritus | D011537 | — | L29 | — | — | — | — | 2 | 2 |
Show 127 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Sufentanil |
| INN | sufentanil |
| Description | Sufentanil is an anilide resulting from the formal condensation of the aryl amino group of 4-(methoxymethyl)-N-phenyl-1-[2-(2-thienyl)ethyl]piperidin-4-amine with propanoic acid. It has a role as an opioid analgesic, a mu-opioid receptor agonist, an anaesthesia adjuvant and an intravenous anaesthetic. It is a member of piperidines, a member of thiophenes, an anilide and an ether. |
| Classification | Small molecule |
| Drug class | narcotic analgesics (fentanyl derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 56030-54-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL658 |
| ChEBI ID | 9316 |
| PubChem CID | 41693 |
| DrugBank | DB00708 |
| UNII ID | AFE2YW0IIZ (ChemIDplus, GSRS) |
Target
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 12,333 documents
View more details
Safety
Black-box Warning
Black-box warning for: Dsuvia, Sufentanil citrate
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5,145 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use